MedPath

PAI-1 Expression in Non-scarring Hair Loss

Terminated
Conditions
Telogen Effluvium
Alopecia Areata
Androgenetic Alopecia
Registration Number
NCT02548689
Lead Sponsor
Northwestern University
Brief Summary

This study will investigate whether subjects who suffer from hair loss have increased levels of PAI-1 compared to age-matched control subjects. The level of PAI-1 expression will be determined in subjects without hair loss and in subjects with non-scarring hair loss, including androgenetic alopecia, telogen effluvium and alopecia areata.

Detailed Description

This study will compare the levels of PAI-1 expression in subjects with different forms of non-scarring hair loss and in these subjects vs normal age-matched controls. Hair loss subjects will have their Northwestern Memorial Hospital and Northwestern Medical Faculty Foundation medical records reviewed to ensure they meet inclusion and exclusion criteria. All subjects will have a 4 mm punch biopsy on the scalp. Tissue PAI-1 levels from scalp skin biopsies will be determined by immunohistochemical staining. Samples will be kept for approximately 15 years, after which time unused samples will be destroyed.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
10
Inclusion Criteria
  • Age-matched control subjects who do not have a history of hair loss
  • A clinical and pathologic diagnosis of androgenetic alopecia, telogen effluvium, alopecia areata or normal scalp skin
  • All subjects must have given signed, informed consent prior to registration in study
Read More
Exclusion Criteria
  • History of previous hair transplantation
  • Current and past use of medications topically on the scalp
  • Clinical or pathologic diagnosis of a scarring alopecia
  • History of inflammatory conditions of the scalp such as psoriasis
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
PAI-1 expression level in scalp skin biopsy samplesBaseline

Tissue PAI-1 expression levels will be determined by immunohistochemistry, a three-layer biotin-strepavidin system. Positive PAI-1 expression per total tissue area will be quantified using the color-picker function in imaging software.The PAI-1 expression found in normal scalps will be compared to those found in scalps with hair loss.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Northwestern University Department of Dermatology

🇺🇸

Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath